Article
Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 1 Dec 2015
Salvador Fernando, Sánchez-Montalvá Adrián, Martínez-Gallo Mónica, Sala-Cunill Anna, Viñas Laura, García-Prat Marina, Aparicio Gloria, Sao Avilés Augusto, Artaza M Ángeles, Ferrer Berta, Molina Israel
Abstract excerpt
BACKGROUND: Benznidazole is the drug of choice for Chagas disease. The major drawback of this drug is the high adverse events rate, being cutaneous reactions the most frequent one, leading to definitive withdrawal of treatment in 15%-30% of patients. METHODS: Prospective observational study where adult Chagas disease patients accepting to receive benznidazole (100 mg/8 hours for 60 days) were included. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.